Introduction
============

Methcathinone (mcat) is an illicit stimulant drug synthesized by oxidation of ephedrine or pseudoephedrine with potassium permanganate. Motor dysfunction, such as hypokinesia and impaired balance, in methcathinone users has been reported in several case series from different countries, and probably develops due to chronic manganese intoxication (Sikk et al., [@B28]; Selikhova et al., [@B25]; Stepens et al., [@B30]). As methcathinone is relatively easy to manufacture using household materials, this poses a significant public health risk. Methcathinone abuse and its preparation with potassium permanganate is quite common in eastern European countries, but there are already signs that the practice is spreading to western countries (De Bie et al., [@B6]).

Molecular mechanisms underlying combined Mn and methcathinone toxicity are poorly understood. Mn neurotoxicity is well known and proposed mechanisms for neuronal death are described in several review articles (Fitsanakis et al., [@B10]; Burton and Guilarte, [@B2]; Curran et al., [@B4]). However, methcathinone has a molecular structure similar to methamphetamine and its pharmacodynamic properties suggest potential toxicity as well (Glennon et al., [@B13]; Rockhold et al., [@B23]; McCann et al., [@B18]). There are no molecular studies on the effect of these substances in combination.

Gene expression profiling using whole-genome microarray screening is a well-established technology to obtain a snapshot of the complex response variables (transcriptome) in biological systems. Expression profiling has great potential for examining molecular pathogenesis and biomarkers of disease. It is a relatively easy to use technology which gives a genome-wide overview of the molecular changes during pathological conditions. Peripheral blood gene expression has been used as a surrogate fingerprint of cerebral neurological diseases (Sharp et al., [@B27]; Sullivan et al., [@B32]; Mohr and Liew, [@B19]; Davies et al., [@B5]). The resulting profile is a complex description of the molecular phenotype and could be used to analyze different acute and chronic conditions.

The aim of this study was to analyze gene expression profiles in chronic methcathinone abusers. In addition, we applied functional genomic analysis to identify gene networks related to this chronic condition.

Materials and Methods
=====================

Study participants
------------------

Twenty illicit methcathinone users and 20 sex- and age-matched controls reporting to be non-drug users and not to be infected with HIV and HCV were enrolled in the present study. Methcathinone was the main drug of abuse. Subjects were divided according to self reported drug abuse history into current or past users (reported having discontinued at least 1 year previously). Main subject characteristics including the results of motor and mental function and quality of life assessment scales are summarized in Table [1](#T1){ref-type="table"} (Hoehn and Yahr, [@B14]; Schwab and England, [@B24]; Folstein et al., [@B11]; Fahn et al., [@B9]; Peto et al., [@B22]). All subjects were positive for hepatitis C virus (HCV). Written informed consent was obtained from all subjects. The study was approved by the ethics committee on human research at Tartu University.

###### 

**Clinical and demographic characteristics**.

  Subject no.                         Sex   Age (years)   HIV   History of drug abuse   Duration of use (years)   UPDRS   Hoehn and Yahr   Schwab and England   PDQ-39   MMSE
  ----------------------------------- ----- ------------- ----- ----------------------- ------------------------- ------- ---------------- -------------------- -------- ------
  1                                   M     47            pos   Current                 6                         13      2,5              95                   24       27
  2                                   F     24            pos   Past                    1                         27      2,5              80                   23       30
  3                                   M     44            pos   Current                 10                        36      3                80                   57       28
  4                                   M     43            pos   Current                 4                         17      2                90                   9        25
  5[\*](#tfn1){ref-type="table-fn"}   M     42            pos   Current                 1                         1       0                100                  0        30
  6                                   M     28            pos   Current                 2                         19      2                95                   53       29
  7                                   M     37            pos   Current                 8                         46      3                70                   64       28
  8                                   F     29            pos   Current                 11                        12      2                90                   46       29
  9                                   M     35            neg   Current                 8                         44      2                90                   66       29
  10                                  M     32            pos   Past                    2                         73      4                55                   61       30
  11                                  M     33            neg   Current                 9                         79      4                55                   71       28
  12                                  M     32            pos   Current                 13                        50      3                70                   55       28
  13                                  M     36            neg   Past                    8                         59      4                50                   43       30
  14                                  F     18            pos   Past                    2                         22      3                75                   44       30
  15                                  M     28            pos   Current                 2                         29      2,5              90                   16       30
  16                                  M     29            neg   Current                 2                         42      3                80                   39       30
  17                                  M     44            neg   Past                    10                        69      4                60                   42       30
  18                                  M     32            pos   Past                    1                         26      3                85                   60       30
  19                                  M     28            pos   Past                    6                         53      3                75                   62       28
  20                                  M     32            pos   Current                 9                         61      2,5              85                   51       30

*UPDRS scores range from 0 to 176 (higher scores indicating more severe disability; Fahn et al., [@B9]). Hoehn and Yahr stages range from 1 to 5 (higher scores indicating more severe disability; Hoehn and Yahr, [@B14]). Schwab and England scores range from 0 to 100 (lower score indicating more severe disability; Schwab and England, [@B24]). PDQ-39 scores from 0 to 100 (higher score indicating worse quality of life; Peto et al., [@B22]). MMSE scores range from 0 to 30 (scores under 23 indicating dementia; Folstein et al., [@B11])*.

*\*Denotes the subject without clinically relevant extrapyramidal syndrome*.

Sample collection and RNA preparation
-------------------------------------

Blood samples from 20 subjects and 20 healthy controls were collected into Tempus tubes (Applied Biosystems, Foster City, USA). Blood was frozen and stored until further processing. RNA extraction from whole blood was performed according to the manufacturer's protocol (PN 4379228C). After RNA extraction, alpha and beta globin mRNA was depleted with GlobinClear Whole Blood Globin Reduction kit (Ambion, Austin, USA). The quality of RNA was analyzed with a Bioanalyzer 2100 (Agilent, Santa Clara, USA) and gene expression profiling was performed with GeneChip Human Gene 1.0 ST Arrays (Affymetrix, Santa Clara, USA) containing probes for all exons of 28,869 genes. We analyzed all the genes on the array without any filtering for presence/absence cells.

Microarray hybridization and analysis
-------------------------------------

In order to label the RNA we used the Affymetrix GeneChip Whole Transcript (WT) Sense Target Labeling Assay (Affymetrix, Santa Clara, USA), which is designed to generate amplified and biotinylated sense-strand targets from the entire expressed genome without bias. Briefly, double-stranded cDNA was synthesized from 300 ng of total RNA by reverse transcription using random hexamers tagged with a T7 promotor primer sequence. The double-stranded cDNA was subsequently used as a template and amplified by T7 RNA polymerase producing many copies of antisense cRNA. In the second cycle of cDNA synthesis, random hexamers were used to prime reverse transcription of the cRNA from the first cycle to produce single-stranded DNA in the sense orientation. This DNA was fragmented with a combination of uracil DNA glycosylase (UDG) and apurinic/apyrimidinic endonuclease 1 (APE 1). DNA was labeled by terminal deoxynucleotidyl transferase (TdT) and hybridization was performed according to the manufacturer's protocol. The arrays were subsequently washed, stained with phycoerythrin streptavidin and scanned according to standard Affymetrix protocol. Images were processed using the Affymetrix Expression Console and the MAS 5.0 algorithm was used to measure quality control parameters.

Statistical analysis
--------------------

The normalized, background subtracted, and modeled expression (Robust Multi-array Analysis, RMA) data (GEO accession number GSE28686) were further analyzed using a linear model combined with Bayesian moderation for standard errors implemented in the Bioconductor *limma* package of the statistical software R[^1^](#fn1){ref-type="fn"} (Ihaka and Gentleman, [@B15]; Smyth, [@B29]). False discovery rate (FDR) was used to address multiple testing corrections (Benjamini and Hochberg, [@B1]; Storey and Tibshirani, [@B31]). Moderated model calculates *B*-value, which is the log-odd that the gene is differentially expressed. B-statistics of zero corresponds to a 50-50 chance that the gene is differentially expressed and B-statistics is automatically adjusted for multiple testing.

Quantitative real-time PCR analysis
-----------------------------------

Eight genes with significant differences and with potentially interesting functions from the gene expression profiling data were further analyzed by means of real-time PCR (RT-PCR). These genes were: C15orf26, GPR15, IGFR1, SNRPN, IFI44L, IFI44, IFI27, and IFNG. RNA was converted into cDNA using the High Capacity cDNA Synthesis kit from Applied Biosystems. TaqMan assays and Gene Expression Master mix was used for the RT-PCR reaction in the SDS 7900 HT system (Applied Biosystems). Sample (20 controls and 20 methcathinone users in four replicates) comparisons were made using Welch's *t*-test.

Functional annotation of differentially expressed genes
-------------------------------------------------------

To define the functional networks of the differentially expressed genes, data were analyzed by ingenuity pathway analysis (IPA, Ingenuity Systems[^2^](#fn2){ref-type="fn"}). A data set containing Affymetrix probeset identifiers and corresponding fold change (log2) values was uploaded. Each gene identifier was mapped to its corresponding gene object in the Ingenuity Pathways Knowledge Base to generate the list of focus genes. Networks of these focus genes were then algorithmically generated based on inter-gene relationships manually curated in the Ingenuity database from published studies. Ingenuity pathway analysis calculates a significance score for each network. The score is generated using a *p*-value calculation, and is displayed as the negative logarithm of that *p*-value. This score indicates the likelihood that the assembly of a set of focus genes into a network could be explained by chance alone (e.g. score of 2 indicates that there is a 1° in 100 chance that the focus genes are together in a network by random chance).

Results
=======

Gene expression profiling with microarrays
------------------------------------------

Comparison of the blood RNA samples isolated from methcathinone users and healthy controls revealed distinct gene expression profiles. Statistically significant differential expression was observed for 326 genes with *p*-values less than 0.05 (FDR adjusted for multiple testing, Table [2](#T2){ref-type="table"}). The magnitudes of expression signal differences (fold change or logFC) between these two groups were generally low -- 17 genes were upregulated in the methcathinone user more than 1.1-fold and only one gene was down-regulated more than 1.1-fold. However, the *B*-statistics values for the list of genes were very high suggesting real biological differences between these groups. A heatmap (Figure [1](#F1){ref-type="fig"}) from unsupervised hierarchical clustering indicates clear clustering of samples into drug users and non-users. However, in the middle of the heatmap, some overlap and mixture between groups occurs. These mcat samples are persons with HIV negative status. Therefore, HIV status has a significant impact on the gene expression profile and is a strong confounding factor.

###### 

**Differential expression analysis of the blood RNA suggests significant differences between study groups**.

  Probeset ID   Gene symbol     logFC   AveExpr   Adj. *p*-value   *B*-value   Gene title
  ------------- --------------- ------- --------- ---------------- ----------- --------------------------------------------------------------
  8081214       GPR15           1.6     8.2       1.11E-04         10.199      G protein-coupled receptor 15
  8046488       CDCA7           0.6     6.5       1.11E-04         9.901       Cell division cycle associated 7
  7917283       MCOLN2          1.0     7.5       4.31E-04         8.329       Mucolipin 2
  7964787       IFNG            1.1     7.1       0.001            7.697       Interferon, gamma
  8081799       TIGIT           1.1     8.4       0.001            7.607       T cell immunoreceptor with Ig and ITIM domains
  8038861       SIGLEC6         0.3     7.3       0.001            6.485       Sialic acid binding Ig-like lectin 6
  8165653       ND1             0.4     13.2      0.001            6.463       NADH dehydrogenase, subunit 1 (complex I)
  8175365       --              0.5     6.5       0.001            6.337       --
  8165674       ND3             0.3     13.0      0.002            6.065       NADH dehydrogenase, subunit 3 (complex I)
  8165648       C7orf11         0.5     12.5      0.002            6.027       Chromosome 7 open reading frame 11
  7946563       --              0.6     11.3      0.002            5.917       --
  7898793       C1QA            0.5     6.0       0.002            5.834       Complement component 1, q subcomponent, A chain
  7903358       VCAM1           0.8     6.0       0.002            5.722       Vascular cell adhesion molecule 1
  8149979       C8orf80         0.5     7.3       0.002            5.684       Chromosome 8 open reading frame 80
  8169249       MID2            0.5     6.7       0.002            5.367       Midline 2
  7983365       TRIM69          0.5     5.9       0.003            5.237       Tripartite motif-containing 69
  8044154       CD8B            0.9     9.1       0.003            5.172       CD8b molecule
  7944739       CRTAM           1.0     7.6       0.003            4.949       Cytotoxic and regulatory T cell molecule
  8053584       CD8A            0.9     9.9       0.003            4.873       CD8a molecule
  8109639       PTTG1           0.5     7.8       0.003            4.751       Pituitary tumor-transforming 1
  7902660       WDR63           0.6     5.3       0.003            4.749       WD repeat domain 63
  8019842       TYMS            0.8     6.7       0.003            4.682       Thymidylate synthetase
  7948420       FABP5           1.0     6.5       0.003            4.662       Fatty acid binding protein 5 (psoriasis-associated)
  8102643       CCNA2           0.6     6.8       0.003            4.653       Cyclin A2
  7917576       GBP5            1.0     11.1      0.004            4.466       Guanylate binding protein 5
  8002975       CDYL2           0.3     7.6       0.004            4.465       Chromodomain protein, Y-like 2
  7930577       CASP7           0.5     8.1       0.004            4.455       Caspase 7, apoptosis-related cysteine peptidase
  8151334       MSC             0.6     7.0       0.004            4.428       Musculin (activated B-cell factor-1)
  7898535       --              0.3     3.9       0.004            4.367       --
  8018352       SLC25A19        0.3     6.7       0.004            4.307       Solute carrier family 25 member 19
  8053690       IGKC            1.0     9.4       0.004            4.291       Immunoglobulin kappa constant
  7981962       SNRPN           0.6     7.1       0.004            4.159       Small nuclear ribonucleoprotein polypeptide N
  7898805       C1QB            0.5     6.8       0.005            4.040       Complement component 1, q subcomponent, B chain
  7940028       SERPING1        1.4     8.7       0.005            3.978       Serpin peptidase inhibitor, clade G (C1 inhibitor), member 1
  7986359       IGF1R           0.7     8.6       0.005            3.914       Insulin-like growth factor-1 receptor
  8116130       FAM153B         −0.6    6.9       0.005            3.898       Family with sequence similarity 153, member B
  8043480       IGKV1OR15-118   0.9     10.9      0.005            3.863       Immunoglobulin kappa variable 1/OR15-118 pseudogene

*Statistical analysis of Affymetrix GeneChip data was performed with the *limma* package for R (Smyth, [@B29]). For significance analysis moderated *t*-statistics combined with simple Bayesian model was used. "Probeset ID" is the Affymetrix ID for probes on the array, "Gene Symbol" is the official HUGO symbol for genes, "logFC" is log2 fold change, "AveExpr" is average expression value (log2), "adj. *p*-value" is FDR adjusted *p*-value, "B-value" is log-odds that the gene is differentially expressed*.

![**Methcathinone users group distinctly on the hierarchical clustering heatmap of blood gene expression levels**. The top 100 genes from the decreasing ordered list of moderated *t*-values were clustered according to similarity in their gene expression patterns. Signals are scaled to *Z*-scores of the rows. The colored bar above the heatmap indicates the grouping variable -- goldenrod for methcathinone user, blue for controls. Column labels at the bottom combine HIV status (positive or negative) with the drug user status (current, past, never). Row labels are gene symbols and the asterisk denotes the subject without clinically relevant extrapyramidal syndrome. Note some overlap between the two groups at the middle of the heatmap.](fgene-02-00042-g001){#F1}

A functional annotation analysis was performed to define gene networks within the observed expression profiles. Relationships among the 326 genes significantly different in methcathinone users compared to control groups included two major networks. The first (with the highest score of 47; score indicates the −log of enrichment *p*-value) contained genes annotated with cell death, antigen presentation, or neurological disease functions (Table [3](#T3){ref-type="table"}, Figure [2](#F2){ref-type="fig"}). A second network (score 42) was related to immunological disease, cellular movement, or cardiovascular disease. Enrichment or activation of these networks suggests that methcathinone users have changes in the genetic pathways related to the function of the nervous and immune systems.

###### 

**Genetic networks significantly changed**.

  Molecules in network                                                                                                                                                                                                                                                      Score   Focus molecules   Top functions
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------- ----------------- --------------------------------------------------------------------------
  **IN METHCATHINONE USERS**                                                                                                                                                                                                                                                                          
  BAK1,CD3,CHI3L2,ENG, EOMES, FBXO6, GBP5, GBP6, GBP7, GBP4 (includes EG:115361), GCH1, growth hormone, HLA-DR, IFI27, IFI30, IFI44L, IFIT3, IFNG, KLF10, MT1F                                                                                                              47      28                Cell death, antigen presentation, neurological disease
  AGER, C2, C1q, C1QA, C1QB, CCR5, CD80, CD81, CD40LG, complement component 1, Creb, CXCR6 (includes EG:10663), ERK,IFI44, IFITM3, IFN&alpha;/&beta                                                                                                                         42      24                Immunological disease, cellular movement, cardiovascular disease
  **In HIV negative methcathinone users, compared to controls**                                                                                                                                                                                                                                       
  Actin, adaptor protein 2, ANK1, Ap1, Ap2 alpha, AP2A1,calmodulin, caspase, CKS2, clathrin, CLU, DAB2, EGF, EIF2AK1, EPB41, F actin, FKBP8, GNAS, GUK1, HDGF, HSPB1, IgG, MPRIP, NFE2, NFkB (complex), NRGN                                                                54      23                Hematological disease, cellular assembly, and organization or cell cycle
  AGTR1B, ANKH, BAT3, betaestradiol, C14ORF45, CA2, CDKN1B, CKS2, CTSA, CUL2, CUL4A, DGKD (includes EG:8527), GRINA, GYPA, HNF4A, MIR135A1, MIRLET7C, MMD, NBL1, NEU1, PHOSPHO1, progesterone                                                                               31      15                Amino acid metabolism, cancer, cell morphology
  **In HIV positive methcathinone users, compared by user status**                                                                                                                                                                                                                                    
  AICDA, CARD8, CCNH, CD40, CD226, CXCL5, DDR1, EIF2AK1, EMP1, ERN1, GYPA, IFIT1L, IFN beta, Iga, Ige, IgG, IGHA1, IGJ, IGLL1, Igm, IL1, IL12 (complex), IL1RAP, interferon alpha, IRAK1BP1, KLF3, MAP4K5, NFkB (complex), NLRP1, RIOK3, Sapk, THBD, TNFSF4, XCL1, ZNF675   46      25                Genetic disorder, immunological disease, cellular movement
  14-3-3, adaptor protein 2, Ap1, ARHGEF12,CAMK2D, CCR3, CDC25A, CREG1, CSPG4, DAB2, DENND4A, DLEU2, E2f, ERK, GAB1, hCG, HDLBP, histone h3, ITGB3, LDLRAP1, LRRFIP1, Mapk, MAX, MYO10, ORC1L, PDGF BB, PGRMC1, Pkc(s), Ras, RGS13, RICS, SKP1, STON2, TFDP2, YBX1          43      24                Cellular assembly and organization, cancer, cell cycle

![**Annotation enrichment analysis indicated that a network including "cell death, antigen presentation, neurological disease" gene functions is significantly enriched in the subjects with methcathinone abuse \[score 47, score is −log (*p-value*)\]**. Red nodes designate upregulated genes and the number indicates log2 fold change (0 is for equal expression). Uncolored nodes are genes in this network that were not in our list of differentially expressed genes.](fgene-02-00042-g002){#F2}

Table [2](#T2){ref-type="table"} includes many genes that are related to immune response, and may be differentially expressed compared to healthy controls because most of drug users were HIV positive. We therefore compared the subgroup of HIV negative drug users to the healthy control group. In this comparison, no genes were significantly different at FDR less than 5%, but 93 genes were different at or below a 30% FDR threshold (Table [A1](#TA1){ref-type="table"} in Appendix). Annotation analysis for this dataset of HIV negative drug users indicated up-regulation (23 genes, score 54) in a network of genes with functions including hematological disease, cellular assembly, and organization or cell cycle (Table [3](#T3){ref-type="table"}). In another subgroup analysis we compared HIV positive subjects according to their user status, current versus discontinued. This comparison should indicate the difference caused by active drug abuse (Table [3](#T3){ref-type="table"}). In this case both groups are HIV and HCV positive, so infection status is balanced. The most significantly enriched network in this comparison included genes in the Genetic Disorder, Immunological Disease, or Cellular Movement categories (25 genes, enrichment score 46). This network supports the involvement of the immune system in the drug abuse induced pathologies.

Quantitative real-time PCR
--------------------------

To further verify changes found with the GeneChip experiment, we performed quantitative RT-PCR and analyzed gene expression levels of eight selected genes. For seven genes, statistically significant differential expression between 20 healthy controls and 20 methcathinone users was seen in the expected direction of change (C15orf26 *p* \< 0.0001, GPR15 *p* \< 0.0001, IGFR1 *p* = 0.0002, SNRPN *p* = 0.038, IFI44L *p* = 0.0264, IFI27 *p* = 0.0450, IFNG *p* \< 0.0001). These results support the validity of our microarray gene expression analysis.

Discussion
==========

In this study, we examined changes in gene expression profiles in peripheral blood induced by methcathinone abuse. All but one of the subjects had a clinically relevant extrapyramidal syndrome. RNA expression patterns of drug users clearly differed from those of healthy controls. Also, RT-PCR results confirmed differences between these two groups. The overlap between controls and HIV negative methcathinone users in the middle of the heatmap (Figure [1](#F1){ref-type="fig"}) suggested that most of the hierarchical clustering was driven by HIV infection status. During recent years several microarray studies of HIV induced alterations in host cell gene expression have been performed using *in vitro* infected primary cells, cell lines, or tissue samples (Giri et al., [@B12]). However, few *in vivo* studies in HIV infected humans have evaluated expression profiles of tissue samples (Masliah et al., [@B17]; Everall et al., [@B8]) or peripheral blood mononuclear cells (Motomura et al., [@B21]; Kottilil et al., [@B16]; Monaco et al., [@B20]). Several of the same apoptosis, antigen presentation, and immune response genes (IFIT3, IFI27, IFI44, IFNG, NFAT, STAT1, TCR, CCR5, ERK, IFITM3, LY6E, IFNG, NFkB, OAS1, PLSCR1) described in previous HIV microarray studies were upregulated in our analysis. Thus peripheral blood can be used for finding gene expression alterations in HIV infected humans. Besides cell death and antigen presentation the genetic network with the highest score was also related to neurological disease, consistent with known associations of HIV infection and neurodegeneration (Clifford et al., [@B3]).

Further minor subgroup analysis of HIV negative users who were all positive for HCV indicated that genes related to cell cycle, cellular growth and proliferation, cancer, and cellular development were upregulated compared to healthy controls. The same pathways have been shown to be involved in HCV induced hepatic changes like cirrhosis, dysplasia, or hepatocellular carcinoma (Wurmbach et al., [@B33]; De Giorgi et al., [@B7]).

As the aim of our study was to analyze the drug abuse effect, we decided to stratify our group of subjects. We analyzed only HIV and HCV positive subjects according to their injection status (past versus current) and a clinical measure of the severity of the neurological syndrome UPDRS. The most significantly enriched network after comparing HIV positive current and past users included genes annotated with functions in Genetic Disorder, Immunological Disease, or Cellular Movement categories (25 genes, enrichment score 46). This network confirms the involvement of the immune system in drug abuse induced pathologies. However, as both comparison groups had neurological symptoms we can not draw any conclusions on the potential causes of the extrapyramidal syndrome. On the other hand, injection status seems to influence immune system and this is one factor involved in the development of a neurodegenerative syndrome. Psychostimulant abuse has been shown to compromise immunological status (Everall et al., [@B8]). Chronic Mn exposure has similar effects on the immune system (Sengupta et al., [@B26]). Thus, both of these factors have potential to induce neurodegeneration.

The UPDRS score reflects the clinical severity of the extrapyramidal syndrome. No significant correlations were found between the duration of Mn--methcathinone use and UPDRS or between blood RNA profiles and UPDRS.

There are several limitations in our study. The main problem is related to the sample organization. Our sample contains many confounding factors -- HIV and HCV infection, different duration of methcathinone use, concomitant consumption of other drugs, alcohol, and tobacco. We have not analyzed the clinical status of the HIV and HCV infections. In addition, several drug abusers were undernourished which makes identification of a relevant control group even more complicated. To overcome these limitations, we have applied complex bioinformatics analytical tools in relatively large samples (*N* = 20 in both groups) that allowed us to perform some cohort stratification. For further studies within methcathinone users more balanced control samples are needed. We have tried to collect similar balanced sample as a control group, but due to the specific and complex nature of our study group it is difficult and time consuming. Ideal controls would be either drug-free HIV and HCV positive subjects or addicts abusing other drugs. We fully understand the limitations caused by the complexity of the problem we analyze. On the other hand, the situation of a non-balanced control sample is quite common in clinical research.
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###### 

**Expression analysis of the blood RNA between HIV negative drug users and the healthy control group**.

  Probeset ID   Gene symbol    logFC   AveExpr   adj. *p*-value   *B*-value   Gene title
  ------------- -------------- ------- --------- ---------------- ----------- ---------------------------------------------------------------------
  7985352       C15orf26       −0.5    6.7       0.3736           −1.890      Chromosome 15 open reading frame 26
  7982090       SNRPN          0.7     2.9       0.9245           −2.305      Small nucleolar RNA, C/D box 115-8
  8018908       DNAH17         0.4     4.9       0.9245           −2.448      Dynein, axonemal, heavy chain 17
  7942983       RNU6-2         0.3     4.0       0.9245           −2.574      RNA, U6 small nuclear 2
  7893226       --             −0.9    6.1       0.9245           −2.588      
  7982068       SNRPN          0.6     2.9       0.9245           −2.784      Small nucleolar RNA, C/D box 115-8
  8059578       --             0.6     6.6       0.9245           −2.791      ENSG00000208057
  7982056       SNRPN          0.7     3.5       0.9245           −2.821      Small nucleolar RNA, C/D box 115-8
  8123336       SNORD45A       0.4     4.5       0.9245           −2.888      Small nucleolar RNA, C/D box 45A
  8167947       --             −1.3    4.4       0.9245           −2.894      ENSG00000211140
  8081214       GPR15          1.1     7.6       0.9245           −2.922      G protein-coupled receptor 15
  8146635       --             0.7     2.5       0.9245           −2.953      ENSG00000211143
  7946054       HBG2           −1.9    11.1      0.9245           −2.963      Hemoglobin, gamma G
  8165653       NDUFS1         −0.3    13.3      0.9245           −2.971      NADH-ubiquinone oxidoreductase chain 1
  7922200       SELP           −0.7    8.5       0.9245           −2.975      Selectin P (granule membrane protein 140 kDa, antigen CD62)
  8051571       --             0.4     4.4       0.9245           −3.019      ENSG00000211163
  7961102       CLEC1B         −0.7    8.0       0.9245           −3.036      C-type lectin domain family 1, member B
  7912582       LOC441873      0.6     5.1       0.9245           −3.048      PRAME family member 11
  8015187       KRTAP1-4       0.4     8.8       0.9245           −3.052      Keratin associated protein 1-4
  8172776       --             −0.4    5.4       0.9245           −3.057      ENSG00000197185
  7944876       NRGN           −0.4    10.7      0.9245           −3.084      Neurogranin (protein kinase C substrate, RC3)
  8112274       ELOVL7         −0.6    9.6       0.9245           −3.109      ELOVL family member 7, elongation of long chain fatty acids (yeast)
  8041711       RNU6-2         0.4     4.2       0.9245           −3.117      RNA, U6 small nuclear 2
  7961026       OVOS2          −1.0    6.5       0.9245           −3.143      Ovostatin 2
  7905481       --             0.6     5.2       0.9245           −3.168      ENSG00000183586
  8144719       LOC100271832   0.8     3.1       0.9245           −3.169      Hypothetical LOC100271832
  8162529       --             0.4     6.3       0.9245           −3.178      ENSG00000209183
  7982088       SNRPN          0.6     3.1       0.9245           −3.181      Small nucleolar RNA, C/D box 115-8
  8130662       --             0.4     4.3       0.9245           −3.203      ENSG00000208409
  7926889       LYZL1          0.5     4.0       0.9245           −3.205      Lysozyme-like 1
  7913976       --             0.4     3.6       0.9245           −3.214      ENSG00000209703
  7963208       --             0.4     3.5       0.9245           −3.222      ENSG00000210200
  7915252       BMP8B          0.4     7.5       0.9245           −3.223      Bone morphogenetic protein 8b
  8178205       HLA-DQA2       0.5     7.9       0.9245           −3.233      Major histocompatibility complex, class II, DQ alpha 1
  8116313       LOC441120      0.4     6.1       0.9245           −3.249      Hypothetical protein LOC729569
  7892934       --             −0.6    7.1       0.9245           −3.275      
  8168687       RN5S9          0.5     4.7       0.9245           −3.280      RNA, 5S ribosomal 9
  8063716       TUBB1          −0.5    11.6      0.9245           −3.293      Tubulin, beta 1
  8111772       DAB2           −0.5    8.7       0.9245           −3.297      Disabled homolog 2

*"Probeset ID" is the Affymetrix ID for probes on the array, "Gene Symbol" is the official HUGO symbol for genes, "logFC" is log2 fold change, "AveExpr" is average expression value (log2), "adj. *p*-value" is FDR adjusted *p*-value, "*B*-value" is log-odds that the gene is differentially expressed*.
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